Larissa N Dooley1, Patricia A Ganz2, Steve W Cole3, Catherine M Crespi4, Julienne E Bower5. 1. Department of Psychology, University of California, Los Angeles, United States. Electronic address: ldooley@psych.ucla.edu. 2. Department of Health Policy & Management, UCLA Fielding School of Public Health, Los Angeles, CA, United States; Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States; Division of Cancer Prevention and Control Research, Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, CA, United States. 3. Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States; Cousins Center of Psychoneuroimmunology, Semel Institute for Neuroscience, Los Angeles, CA, United States. 4. Department of Biostatistics, UCLA Fielding School of Public Health, Los Angeles, CA, United States. 5. Department of Psychology, University of California, Los Angeles, United States; Division of Cancer Prevention and Control Research, Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, CA, United States; Cousins Center of Psychoneuroimmunology, Semel Institute for Neuroscience, Los Angeles, CA, United States; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States.
Abstract
BACKGROUND: Inflammation contributes to the development of depression in a subset of individuals, but risk factors that render certain individuals particularly vulnerable to inflammation-associated depression are undetermined. Drawing from animal studies showing that reduced neuroplasticity mediates effects of inflammation on depression, we hypothesized that individuals genetically predisposed to lower levels of neuroplasticity would be more susceptible to inflammation-associated depression. The current study examined whether the Met allele of the BDNF Val66met polymorphism, which predisposes individuals to reduced levels of brain-derived neurotrophic factor (BDNF), a protein vital for neuroplasticity, moderates the association between inflammation and depressive symptoms. METHODS: Our sample was 112 women with early-stage breast cancer who had recently completed cancer treatment, which can activate inflammation. Participants provided blood for genotyping and assessment of circulating inflammatory markers, and completed a questionnaire assessing depressive symptoms, including somatic, affective, and cognitive dimensions. RESULTS: There was a significant interaction between C-reactive protein (CRP) and the BDNF Val66met polymorphism in predicting cognitive depressive symptoms (p=.004), such that higher CRP was related to more cognitive depressive symptoms among Met allele carriers, but not among Val/Val homozygotes. Post-hoc longitudinal analyses suggested that, for Met carriers, higher CRP at baseline predicted higher cognitive depressive symptoms across a one-year follow-up period (p<.001). CONCLUSION: The BDNF Met allele may be a risk factor for inflammation-associated cognitive depressive symptoms among breast cancer survivors. Women with breast cancer who carry this genotype may benefit from early identification and treatment. LIMITATION: BDNF genotype is an indirect measure of BDNF protein levels. Published by Elsevier B.V.
BACKGROUND:Inflammation contributes to the development of depression in a subset of individuals, but risk factors that render certain individuals particularly vulnerable to inflammation-associated depression are undetermined. Drawing from animal studies showing that reduced neuroplasticity mediates effects of inflammation on depression, we hypothesized that individuals genetically predisposed to lower levels of neuroplasticity would be more susceptible to inflammation-associated depression. The current study examined whether the Met allele of the BDNFVal66met polymorphism, which predisposes individuals to reduced levels of brain-derived neurotrophic factor (BDNF), a protein vital for neuroplasticity, moderates the association between inflammation and depressive symptoms. METHODS: Our sample was 112 women with early-stage breast cancer who had recently completed cancer treatment, which can activate inflammation. Participants provided blood for genotyping and assessment of circulating inflammatory markers, and completed a questionnaire assessing depressive symptoms, including somatic, affective, and cognitive dimensions. RESULTS: There was a significant interaction between C-reactive protein (CRP) and the BDNFVal66met polymorphism in predicting cognitive depressive symptoms (p=.004), such that higher CRP was related to more cognitive depressive symptoms among Met allele carriers, but not among Val/Val homozygotes. Post-hoc longitudinal analyses suggested that, for Met carriers, higher CRP at baseline predicted higher cognitive depressive symptoms across a one-year follow-up period (p<.001). CONCLUSION: The BDNF Met allele may be a risk factor for inflammation-associated cognitive depressive symptoms among breast cancer survivors. Women with breast cancer who carry this genotype may benefit from early identification and treatment. LIMITATION: BDNF genotype is an indirect measure of BDNF protein levels. Published by Elsevier B.V.
Entities:
Keywords:
BDNF; Beck Depression inventory-II; Breast cancer; CRP; Depression; Inflammation
Authors: D L Musselman; A H Miller; M R Porter; A Manatunga; F Gao; S Penna; B D Pearce; J Landry; S Glover; J S McDaniel; C B Nemeroff Journal: Am J Psychiatry Date: 2001-08 Impact factor: 18.112
Authors: Lucile Capuron; Jane F Gumnick; Dominique L Musselman; David H Lawson; Andrea Reemsnyder; Charles B Nemeroff; Andrew H Miller Journal: Neuropsychopharmacology Date: 2002-05 Impact factor: 7.853
Authors: Michael F Egan; Masami Kojima; Joseph H Callicott; Terry E Goldberg; Bhaskar S Kolachana; Alessandro Bertolino; Eugene Zaitsev; Bert Gold; David Goldman; Michael Dean; Bai Lu; Daniel R Weinberger Journal: Cell Date: 2003-01-24 Impact factor: 41.582
Authors: Leah M Pyter; Lorena P Suarez-Kelly; William E Carson; Jasskiran Kaur; Joshua Bellisario; Savannah R Bever Journal: Behav Brain Res Date: 2017-05-04 Impact factor: 3.332
Authors: Gee Su Yang; Sreelakshmy Kumar; Susan G Dorsey; Angela R Starkweather; Debra Lynch Kelly; Debra E Lyon Journal: Support Care Cancer Date: 2018-10-20 Impact factor: 3.603
Authors: Larissa N Dooley; Kate R Kuhlman; Theodore F Robles; Naomi I Eisenberger; Michelle G Craske; Julienne E Bower Journal: Neurosci Biobehav Rev Date: 2018-09-07 Impact factor: 8.989
Authors: Jong Y Park; Cecile A Lengacher; Richard R Reich; Carissa B Alinat; Sophia Ramesar; Alice Le; Carly L Paterson; Michelle L Pleasant; Hyun Y Park; John Kiluk; Hyo Han; Roohi Ismail-Khan; Kevin E Kip Journal: Transl Behav Med Date: 2019-07-16 Impact factor: 3.626
Authors: Brian S Wolff; Sumiyya A Raheem; Sarah A Alshawi; Jeniece M Regan; Li Rebekah Feng; Leorey N Saligan Journal: PLoS One Date: 2020-07-02 Impact factor: 3.240